BFRI BIOFRONTERA INC

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call
Date:Thursday, August 14, 2025
Time:10:00am ET
Conference Call:1-877-877-1275 (U.S.)

1-412-858-5202 (international)
Webcast:
  

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit  and follow Biofrontera on  and .

Contacts:

Investor Relations

Andrew Barwicki

1-516-662-9461



EN
04/08/2025

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz...

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera I...

5h / 36m 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Amelu...

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmace...

August 25, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Pro...

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update. Highlights from the first six months of 2025 included the following: Total revenues for the second quarter of 2025 were $9.0 million, a 15% increase from the same period...

August 13, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company’s commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company’s manage...

August 11, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on...

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time. Conference...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch